Maze CSBO exercises options, sells 7,500 shares
Maze Therapeutics, Inc. chief business officer Atul Dandekar exercised stock options for 7,500 shares of common stock at $10.42 per share and on the same day sold 7,500 shares in an open-market transaction at a weighted average price of $25.3732 per share.
Rhea-AI Filing Summary
Maze Therapeutics, Inc. chief business officer Atul Dandekar exercised stock options for 7,500 shares of common stock at $10.42 per share and on the same day sold 7,500 shares in an open-market transaction at a weighted average price of $25.3732 per share. Following these transactions, he directly holds 10,503 shares of Maze common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, indicating the timing was set in advance rather than decided opportunistically.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,500 shares ($112K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Dandekar Atul
Role
CSBO
Sold
7,500 shs ($190K)
Approx. gross sale proceeds
$190K
Approx. exercise cost
$78K
Approx. pre-tax spread
$112K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,500 | $10.42 | $78K |
| Sale | Common Stock | 7,500 | $25.3732 | $190K |
Holdings After Transaction:
Stock Option (Right to Buy) — 44,143 contracts (Direct);
Common Stock — 10,503 shares (Direct)
Footnotes (3)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.08 to $25.77 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.
Key Figures
Shares sold: 7,500 shares
Sale price (weighted average): $25.3732 per share
Sale price range: $25.08–$25.77 per share
+5 more
8 metrics
Shares sold
7,500 shares
Open-market sale of common stock
Sale price (weighted average)
$25.3732 per share
Common stock sale on April 29, 2026
Sale price range
$25.08–$25.77 per share
Range of individual trade prices
Options exercised
7,500 shares
Stock option exercise converting to common stock
Option exercise price
$10.42 per share
Stock Option (Right to Buy) conversion price
Shares held after
10,503 shares
Direct Maze common stock holdings post-transaction
Net buy/sell shares
-7,500 shares
Net from reported buy/sell transactions
Rule 10b5-1 plan adoption date
September 29, 2025
Date trading plan was adopted
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The reported price in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) listed as a derivative security"
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
open-market sale financial
"transaction_action: open-market sale for the common stock transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Maze Therapeutics (MAZE) executive Atul Dandekar report on this Form 4?
Atul Dandekar reported exercising stock options for 7,500 Maze Therapeutics common shares at $10.42 each, then selling 7,500 shares in the open market. These combined transactions left his direct holdings at 10,503 Maze common shares after the reported date.
What stock option exercise did Atul Dandekar report for Maze Therapeutics (MAZE)?
He exercised a stock option covering 7,500 Maze Therapeutics common shares at an exercise price of $10.42 per share. The option was fully vested, with vesting completed on March 17, 2025, before the reported transactions occurred.
What type of transaction pattern does the Maze Therapeutics (MAZE) Form 4 show?
The filing shows an exercise-and-sell pattern: options for 7,500 Maze shares were exercised at $10.42, and 7,500 shares were then sold. This effectively converts an existing option position into cash, while leaving his direct share count unchanged versus before the exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
